Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 38 articles: HTML format

Single Articles

September 2023
1. KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al
   Circulating proteome for pulmonary nodule malignancy.
   J Natl Cancer Inst. 2023;115:1060-1070.
   PubMed     Abstract available
   
   
   August 2023
2. RAPHAEL J, Richard L, Lam M, Blanchette P, et al
   Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice.
   J Natl Cancer Inst. 2023;115:949-961.
   PubMed     Abstract available
   
   
   July 2023
3. CHANG A, Flores RM, Taioli E
   Unequal Racial Distribution of Immunotherapy for Late-Stage Non-Small Cell Lung Cancer.
   J Natl Cancer Inst. 2023 Jul 8:djad132. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2023
4. MILANO MT, Salama JK, Chmura SJ
   Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?
   J Natl Cancer Inst. 2023;115:605-607.
   PubMed    
   
   
   
5. WANG XS, Bai YF, Verma V, Yu RL, et al
   Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
   J Natl Cancer Inst. 2023;115:742-748.
   PubMed     Abstract available
   
   
   
6. FENG X, Wu WY, Onwuka JU, Haider Z, et al
   Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
   J Natl Cancer Inst. 2023 Jun 1:djad071. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2023
7. CARROLL NM, Burnett-Hartman AN, Rendle KA, Neslund-Dudas CM, et al
   Smoking status and the association between patient-level factors and survival among lung cancer patients.
   J Natl Cancer Inst. 2023 May 25:djad098. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. 
   Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer.
   J Natl Cancer Inst. 2023 May 18:djad084. doi: 10.1093.
   PubMed    
   
   
   
9. RUSTHOVEN CG, Staley AW, Gao D, Yomo S, et al
   Comparison of First-Line Radiosurgery for Small-Cell and Non-Small Cell Lung Cancer Brain Metastases (Cross-FIRE).
   J Natl Cancer Inst. 2023 May 4:djad073. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2023
10. UNGER JM, Qian L, Redman MW, Tavernier SS, et al
    Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
    J Natl Cancer Inst. 2023;115:437-446.
    PubMed     Abstract available
    
    
    
11. OH DL, Schumacher K, Yang J, Wang K, et al
    Disparities in cancer incidence by rurality in California.
    J Natl Cancer Inst. 2023;115:385-393.
    PubMed     Abstract available
    
    
    February 2023
12. SELBY K, Sedki M, Levine E, Kamineni A, et al
    Test performance metrics for breast, cervical, colon and lung cancer screening: a systematic review.
    J Natl Cancer Inst. 2023 Feb 8:djad028. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2022
13. SIRUFO MM, Ginaldi L, De Martinis M
    RE: Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Dec 19:djac235. doi: 10.1093.
    PubMed    
    
    
    November 2022
14. HEIDEN BT, Eaton DB, Chang SH, Yan Y, et al
    Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer.
    J Natl Cancer Inst. 2022 Nov 29:djac208. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. LI M, Liao K, Chen AJ, Cascone T, et al
    Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
    J Natl Cancer Inst. 2022 Nov 8. pii: 6809139. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. DI FEDERICO A, De Giglio A, Gelsomino F, Sperandi F, et al
    Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis.
    J Natl Cancer Inst. 2022 Nov 2. pii: 6794208. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2022
17. YOU S, Kim M, Hoi XP, Lee YC, et al
    Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.
    J Natl Cancer Inst. 2022;114:1380-1391.
    PubMed     Abstract available
    
    
    September 2022
18. WARKENTIN MT, Tammemagi MC, Espin-Garcia O, Budhathoki S, et al
    Lung Cancer Absolute Risk Models for Mortality in Asian Population using China Kadoorie Biobank.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694851. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. PELLINEN T, Paavolainen L, Martin-Bernabe A, Papatella Araujo R, et al
    Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694853. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2022
20. SEDANI AE, Davis OC, Clifton SC, Campbell JE, et al
    Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework Driven Systematic Review.
    J Natl Cancer Inst. 2022 Aug 22. pii: 6673083. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. VOGTMANN E, Hua X, Yu G, Purandare V, et al
    The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies.
    J Natl Cancer Inst. 2022 Aug 5. pii: 6656358. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2022
22. BROUWER AF, Engle JM, Jeon J, Meza R, et al
    Sociodemographic survival disparities for lung cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Jul 22. pii: 6648464. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. TAYLOR KL, Williams RM, Li T, Luta G, et al
    A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting.
    J Natl Cancer Inst. 2022 Jul 12. pii: 6633937. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
24. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    PubMed     Abstract available
    
    
    May 2022
25. GABRIEL AAG, Atkins JR, Penha RCC, Smith-Byrne K, et al
    Genetic analysis of lung cancer and the germline impact on somatic mutation burden.
    J Natl Cancer Inst. 2022 May 2. pii: 6576636. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
26. 
    Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2022 Apr 1. pii: 6561908. doi: 10.1093.
    PubMed    
    
    
    February 2022
27. TANAKA I, Dayde D, Tai MC, Mori H, et al
    SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
    J Natl Cancer Inst. 2022;114:290-301.
    PubMed     Abstract available
    
    
    December 2021
28. CHOI E, Luo SJ, Aredo JV, Backhus LM, et al
    The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459177. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
29. ISLAMI F, Ward EM, Sung H, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
    J Natl Cancer Inst. 2021;113:1648-1669.
    PubMed     Abstract available
    
    
    
30. GAVRIELATOU N, Shafi S, Gaule P, Rimm DL, et al
    PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.
    J Natl Cancer Inst. 2021;113:1613-1614.
    PubMed    
    
    
    August 2021
31. HOPKINS AM, Kichenadasse G, Logan JM, Rowland A, et al
    RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 27. pii: 6358733. doi: 10.1093.
    PubMed    
    
    
    
32. ZHAO W, Zhu B, Hutchinson A, Pesatori AC, et al
    Clinical Implications of Inter- and Intra-Tumor Heterogeneity of Immune Cell Markers in Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 17. pii: 6353611. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. DEROUEN MC, Canchola AJ, Thompson CA, Jin A, et al
    Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females.
    J Natl Cancer Inst. 2021 Aug 4. pii: 6338453. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
34. CHOI E, Sanyal N, Ding VY, Gardner RM, et al
    Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
    J Natl Cancer Inst. 2021 Jul 13. pii: 6320070. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2021
35. WANG X, Ricciuti B, Alessi JV, Nguyen T, et al
    Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Jun 11. pii: 6296846. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2021
36. VERHOEVEN DC, Chollette V, Lazzara EH, Shuffler ML, et al
    The Anatomy and Physiology of Teaming in Cancer Care Delivery: A Conceptual Framework.
    J Natl Cancer Inst. 2021;113:360-370.
    PubMed     Abstract available
    
    
    December 2020
37. MITCHELL AP, Bach PB
    Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.
    J Natl Cancer Inst. 2020;112:1177-1178.
    PubMed    
    
    
    July 2020
38. TAKVORIAN SU, Balogh E, Nass S, Valentin VL, et al
    Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action.
    J Natl Cancer Inst. 2020;112:663-670.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: